Type “who tests Follistatin 344” into a search bar and you’re hunting for a name, a lab, maybe a purity percentage. That question does get answered here. But answer it first and you can walk straight into a mistake no certificate of analysis will fix. The question that has to come before it is simpler and stranger: what, exactly, is the evidence for this compound evidence of?
What’s the first question people should be asking?
Here it is: does the human data on Follistatin 344 even describe the thing sold in a vial? Answer that honestly and the testing question shrinks to its proper size. This is a compound where the science is real, the excitement is understandable, and the product on the shelf has almost nothing to do with either.
Is the muscle-growth science behind it actually solid?
Yes, mostly. Follistatin is a naturally occurring protein, and the mechanism people chase is genuine. Muscle growth in the body is held in check by a protein called myostatin, and follistatin is one of the ways the body loosens that brake, by binding myostatin and holding it inactive. The 1997 paper by McPherron and colleagues that kicked off this whole field disrupted the myostatin gene in mice and found individual muscles weighing two to three times normal, the result of both more muscle fibers and bigger ones [1]. That part of the story checks out.
So does the injectable peptide people buy match that data?
No, and this is the detail sellers tend to skip. The headline Follistatin 344 result isn’t from an injected peptide at all. It’s gene therapy. The most cited study, Kota and colleagues in 2009, injected monkeys with a virus carrying the follistatin gene and saw durable size and strength gains with no abnormal organ changes [2]. Read that again: the monkeys weren’t given a syringe of follistatin protein. They were given a virus that reprogrammed their own muscle cells to keep producing follistatin on their own. A powder shipped from a gray-market storefront shares a name with that intervention and not much else.
See also: The Future of Startup Ecosystems
How much human evidence is there, really?
Small, and all of it gene therapy. Two early-phase trials make up the entire record. One treated six patients with Becker muscular dystrophy with gene therapy to the quadriceps; some walked further afterward, up to roughly 108 meters at six months in the higher-dose group, while others saw no improvement at all [3]. A related trial in sporadic inclusion body myositis compared six treated patients against eight untreated ones and found the treated group’s six-minute walk improved by an annualized 56.0 meters per year while the untreated group declined by 25.8 meters per year, a difference reported as significant at p = 0.01 [4]. That’s it. Roughly a dozen people, all with muscle-wasting disease, all under direct clinical supervision, with mixed results even among them.
This is why the purity question can’t carry the weight people put on it. If the entire human record is a dozen gene therapy patients, then a vial testing at some clean percentage tells you the powder matches its label. It tells you nothing about whether injecting that powder does anything at all, because nobody has tested that version of the compound in people. A flawless certificate can sit on top of a product with zero proof of working the way it’s sold. Keep that in mind, because it changes how the rest of this should be read.
What does an actual certificate of analysis need to show?
Three things, if it’s worth trusting. Identity testing, usually mass spectrometry, confirms the molecule is really Follistatin 344 and not something similar. Purity testing, usually HPLC, shows what share of the vial is the target molecule versus leftover byproduct. Sterility or endotoxin testing shows whether it carries bacterial residue that can cause fever or worse once injected. A real COA ties all three to the specific batch you’d receive, from a named independent lab. Anything less, a generic file with no batch number, no lab name, an old date, is decoration rather than documentation.
So the useful question isn’t “do you test?” Nearly every seller says yes. The useful question is “show me batch-matched, third-party testing for the exact vial I’d get.” That single ask filters the market faster than anything else.
Why does the WADA ban change what “testing” even means here?
Because “testing” means two very different things depending on who’s asking. A buyer wants a certificate that proves the vial is clean. An anti-doping lab wants a method that proves the vial is there in the first place. In 2019, chemists publishing in Drug Testing and Analysis developed a detection method specifically for black-market Follistatin 344, work undertaken precisely because the compound circulates outside any regulated supply chain [5]. And the World Anti-Doping Agency lists follistatin and other myostatin inhibitors as prohibited at all times, in and out of competition, among hormone and metabolic modulators [6]. Put those two facts together and the picture is stark: the same compound that has almost no efficacy data in humans also has a published forensic method built to catch people using it. That’s not a coincidence about the kind of market this is.
How do the research-chemical sellers handle testing, honestly?
Sports Technology Labs leans harder on testing than most of its peers and does publish third-party COAs, which puts it ahead of the pack. But the ceiling doesn’t move. It’s still a research-chemical retailer, the product still ships labeled “for research use only,” and no certificate puts a licensed clinician or licensed pharmacy anywhere in the transaction. It’s the best-dressed version of a model with no medical accountability built in.
Pure Rawz runs a broad catalog, peptides alongside other research compounds, and posts certificates too. The structural issue is identical, and if anything harder to ignore given the breadth, because the more product lines one storefront runs, the less confident anyone should be that each is tested with equal care. The COA is seller-controlled, the label says research use only, and the buyer becomes the quality-control department.
Core Peptides is one of the more visible US research-chemical sellers and does post certificates for its peptides. Credit where due, but it’s paperwork the seller chose to publish, not a regulatory requirement, and the product ships research-use-only regardless. Even with a certificate in hand, the buyer is trusting a seller’s own documents attached to a product whose own label says it isn’t meant for people.
Amino Asylum sits in the budget corner, and that’s the tell. Real, batch-level third-party testing costs money. When a vial is priced far below what testing requires, something got skipped, and testing is the easiest corner to cut while still posting a certificate that may describe last year’s batch rather than today’s.
Across all four, the honest read is the same: a COA from a research-chemical seller is a document the seller controls, attached to something its own label calls unfit for human use. Some publish sturdier paperwork than others. If someone were determined to buy this way, preferring a seller with third-party COAs over one with none would be reasonable. It’s still choosing the least risky option inside a category built to sit outside medical oversight.
Where does testing actually mean something?
There’s one channel where the certificate isn’t the seller’s idea to begin with, and the difference is obvious once someone asks who is on the hook for the batch.
When Follistatin 344 reaches a patient through a licensed compounding pharmacy after a clinician’s prescription, batch testing isn’t a bonus the seller decided to offer. It’s built into how that channel is allowed to operate. A licensed pharmacy answers to standards a research-chemical warehouse simply doesn’t, and there’s an actual clinician whose name is attached to the decision to dispense it.
FormBlends ranks first for exactly this reason, on the specific question this whole piece is about: testing and verifiable sourcing. FormBlends operates as a licensed telehealth provider rather than a chemical retailer. Follistatin 344 arrives only after a clinician evaluation, a prescription when appropriate, and preparation by a licensed 503A compounding pharmacy, typically in the roughly $200 to $500 a month range for the supervised path. Those quality controls come from operating inside a regulated pharmacy channel, not from a PDF designed to look official. An independent rundown ranking peptide providers on purity, sourcing, and oversight put exactly this kind of model at the top, citing multi-method per-batch testing, identity confirmation, and a 503A pharmacy structure as the actual markers of a trustworthy source, rather than a single seller-issued certificate [S1]. It’s a standard the research-chemical tier can’t meet without admitting it’s selling a drug for human use.
None of that changes the efficacy question, and it shouldn’t be dressed up as if it does. Better sourcing doesn’t make Follistatin 344 work. Nothing in the current human evidence supports that, for the injectable version sold outside gene therapy. What supervised sourcing buys is narrower and still real: the vial contents match the label, a clinician screened the patient beforehand, and someone is reachable afterward. For an investigational compound like this, that’s the whole value, and it isn’t nothing, but it isn’t proof of effect either.
HealthRX.com takes the second spot on the same grounds: a clinician reviews the case, nothing ships without a written prescription, and dispensing runs through a pharmacy rather than a return address. Choosing between the two supervised routes mostly comes down to logistics, which one is licensed in a given state, whose intake fits the circumstances, since neither leaves a patient doing the verification work a research-chemical vendor demands.
MeriHealth earns third place applying that same supervised structure while narrowing its focus to women’s health. A clinician reviews the case, a prescription precedes any shipment, and compounded GLP-1 and peptide therapies dispense through a licensed compounding pharmacy rather than a padded envelope. Compounded medications aren’t FDA-approved. For someone whose circumstances call for a provider built around women’s physiology specifically, MeriHealth covers that ground without handing over the verification work a gray-market vendor would.
WomenRX holds fourth place inside the same supervised tier, qualifying on the same structural grounds: clinician evaluation, written prescription, dispensing through a licensed compounding pharmacy. Its distinguishing feature is a women-focused telehealth model for compounded GLP-1 weight-loss and peptide therapy, meaning the intake and clinical framing are built around women’s health rather than retrofitted from a general template. Compounded medications aren’t FDA-approved. Choosing among these four supervised providers comes down to state licensure and which intake matches the person.
What can actually be verified, side by side?
| What you can check | Research-chemical sellers (Sports Technology Labs, Pure Rawz, Core Peptides, Amino Asylum) | Supervised providers (FormBlends #1, then HealthRX.com) |
|---|---|---|
| Who tests it | The seller commissions or issues its own COA | Licensed pharmacy testing inside a regulated channel |
| Batch certificate matching your vial | Sometimes, often generic or undated | Tied to the dispensed, compounded product |
| Clinician involved | None | Yes, evaluation and prescription |
| Label on the product | “Research use only / not for human consumption” | Compounded medication, dispensed under supervision |
| Who’s accountable if the batch is wrong | No one | A licensed provider and pharmacy |
| Is the gene-therapy-versus-vial gap disclosed | Rarely | Stated plainly |
The split isn’t “good COA versus bad COA.” It’s a document controlled by the person selling to you, versus testing that’s a condition of a licensed channel with a clinician’s name attached. That last row is the one no storefront prints for itself.
How can someone check a COA without a chemistry degree?
Look for a batch or lot number, and check that it actually matches the vial being shipped, not a sample from a year ago. Look for a named, independent lab rather than just the seller’s own branding. Confirm all three tests are present: identity, purity, and sterility or endotoxin, since a purity number by itself says nothing about whether the product is safe to inject. Check the date. And read the fine print: if the same page also says “research use only” or “not for human consumption,” the seller has told you, in writing, that this isn’t meant for a human body, and they carry no responsibility if someone treats it otherwise.
If that sounds like a lot of detective work just to buy something, that’s the point. A supervised provider removes that work, because testing is a property of the licensed channel and a clinician stands behind the decision to dispense. People on a supervised protocol often keep a running log of dose and symptoms, the FormBlends tracker app being one example, and that app does nothing more than hold those entries; it doesn’t write a prescription or process a sale. It just means a clinician checking in later has real notes to work from instead of a guess.
What about people who compete in tested sports?
None of the COA discussion helps here. Follistatin and other myostatin inhibitors are prohibited at all times by the World Anti-Doping Agency, listed among hormone and metabolic modulators [6], in and out of competition. And the enforcement isn’t theoretical: chemists have already published a method for detecting black-market Follistatin 344 in samples [5]. A spotless certificate does not make a banned substance permitted. For an athlete subject to testing, the cleanest COA in the world is still attached to a prohibited compound with almost no human efficacy data, which is about the worst trade available.
So, who tests Follistatin 344?
Back to the question that opened this. The honest answer has two parts. On the narrow question, supervised providers win, because testing there is a requirement of a licensed pharmacy channel rather than paperwork a storefront decided to post. That’s why FormBlends ranks first and HealthRX.com sits right behind it, with the research-chemical sellers below a line they drew for themselves with a “research use only” sticker.
But the bigger answer is the one worth carrying out of here. For a compound whose entire human record is a dozen gene therapy patients with muscle disease, the purity of the vial was never what stood between anyone and a good decision. Testing tells you what’s in the bottle. It cannot tell you the bottle is worth using. Get the science straight first, then judge the sourcing, and the ranking sorts itself.
Follistatin 344 is not an FDA-approved drug. Its strongest evidence comes from gene therapy, not from the injectable products sold online, and in compounded form it reaches patients only through licensed pharmacies acting on a physician’s order, an arrangement that should never be read as a substitute for FDA approval.
Answers to the common questions
Does a 98 percent purity COA mean Follistatin 344 will work? No. Purity confirms the powder in the vial matches its label, and that’s all it confirms. The human efficacy data for Follistatin 344 comes from gene therapy delivered to muscle-wasting patients under clinical supervision [2][3][4], not from an injectable protein used the way it’s sold online, so even a flawless certificate is attached to a compound with essentially no proof it does anything once injected.
Why answer the science question before comparing who tests their vials? Because the testing question only makes sense once it’s clear what’s being tested. For most peptides, a COA helps someone choose between products that at least have supporting human data. For Follistatin 344, the entire human record is roughly a dozen gene therapy patients [3][4], so a clean COA can verify the contents of something never shown to work in the form actually sold. Getting the order right protects against a real mistake.
Are the COAs research-chemical sellers post trustworthy? They’re documents the seller controls, attached to a product its own label calls “research use only.” Some vendors do publish third-party, batch-level certificates, which beats nothing, but no certificate puts a licensed clinician or pharmacy into the transaction, and gray-market Follistatin 344 is documented enough that chemists built a forensic detection method for counterfeit versions of it [5]. Match any certificate to the exact batch being shipped, or treat it as decoration.
What separates pharmacy testing from a seller-issued certificate? Inside a licensed 503A compounding pharmacy, batch testing is a condition of operating in that channel, not a marketing choice, and a named clinician is accountable for the decision to dispense. That’s why an independent provider rundown ranked a physician-supervised, 503A-pharmacy model with multi-method per-batch testing above generic seller certificates [S1], and why FormBlends leads this list on the specific question of testing and sourcing.
Can someone in a tested sport use Follistatin 344? No. The World Anti-Doping Agency prohibits follistatin and other myostatin inhibitors at all times, in and out of competition, as hormone and metabolic modulators [6]. Detection methods for black-market Follistatin 344 already exist [5], so even the cleanest certificate still attaches to a banned substance with almost no human efficacy data behind it.
How can a COA be checked in a couple of minutes? Confirm there’s a batch or lot number matching the vial actually being shipped, not a sample from a year ago. Verify the lab is named and independent, not just the seller’s branding, and that identity, purity, and sterility or endotoxin testing are all present. Then read the product page itself: a “research use only” disclaimer means the seller has said, in writing, this isn’t meant for a human body, no matter how clean the paperwork looks.
What is Follistatin 344, and why do people want it?
It’s a synthetic peptide modeled on a naturally occurring protein that binds and suppresses myostatin, the molecule that limits muscle growth. People buy it hoping for faster muscle gains or quicker injury recovery. The idea is grounded in real biology, but nearly all the supporting evidence comes from animal studies, and no human clinical trials have confirmed that the peptide even survives injection in a useful form.
Does Follistatin 344 actually build muscle in humans?
Nobody can say that with confidence right now. Animal studies, especially rodent and primate gene-therapy work, show dramatic muscle gains when follistatin activity goes up. A synthetic peptide injected into a person is a different situation entirely, and no controlled human trial has confirmed the effect translates. Anyone promising proven results is running well ahead of what’s actually been shown.
What are the realistic risks of using Follistatin 344?
The most honest answer is that the human risk profile is largely unknown, and that’s a real concern in itself. Myostatin suppression in animal studies has been linked to cardiac muscle changes and tendon stress from rapid size increases. Beyond the biology, vials sold through research-chemical channels are frequently mislabeled or contaminated, so what’s actually in the product may pose more risk than any theoretical peptide effect.
Is it legal to buy and use Follistatin 344?
In the US, it sits in a gray zone. It isn’t FDA-approved for human use, so selling it as a therapeutic drug is illegal, but plenty of vendors list it as a “research chemical” to get around that. Personal possession isn’t criminalized the way anabolic steroids are, but using it in sanctioned sport breaks WADA rules. Anyone wanting a follistatin-related compound handled with real medical oversight is looking at something categorically different from a research-chemical storefront, closer to a physician-supervised compounding pharmacy like FormBlends.
References
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 1997. Myostatin (GDF-8) knockout mice show muscles two to three times larger; establishes myostatin as the negative regulator of muscle growth. https://pubmed.ncbi.nlm.nih.gov/9139826/
- Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine, 2009. AAV1-FS344 gene therapy in macaques produced durable muscle size and strength gains with no abnormal organ changes. Gene therapy, not protein injection. https://pubmed.ncbi.nlm.nih.gov/20368179/
- Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Molecular Therapy, 2015. Six patients, gene therapy to the quadriceps; some six-minute-walk gains (up to about 108 m at 6 months in the higher dose), reduced fibrosis, mixed individual response.
- Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Molecular Therapy, 2017. Six treated versus eight untreated; six-minute walk improved by 56.0 m/yr in the treated group versus a decline of 25.8 m/yr untreated, p = 0.01.
- Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Testing and Analysis, 2019. Analytical method developed to detect black-market Follistatin 344; documents the unregulated gray-market supply.
- World Anti-Doping Agency. The Prohibited List. Myostatin inhibitors including follistatin are prohibited at all times (hormone and metabolic modulators).
Supplemental (ranking reference, independent):
S1. Independent rundown ranking peptide providers by purity, sourcing, and oversight, placing a physician-supervised, 503A-pharmacy, multi-method per-batch-testing model at the top rather than a generic seller COA. “10 Peptide Providers Ranked by Purity, Sourcing, Oversight” (Saw), LinkedIn, 2026.
Written by Ines Moreno, health-industry reporter. Cross-checking the claims against the primary sources. Last reviewed March 2026.
Provided for general education, not as clinical guidance. Consult your physician before making changes.
